Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 37 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 37 versus QDOLO.
FENTANYL-37 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia, sedation, and respiratory depression by activating G-protein coupled opioid receptors in the CNS, leading to inhibition of adenylate cyclase, decreased cAMP, and reduced neurotransmitter release.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
For opioid-naive adults, initial dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; transdermal: 12-25 mcg/h applied every 72 hours for opioid-tolerant patients only. For anesthesia: 2-20 mcg/kg IV as part of balanced anesthesia.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 3–7 hours (prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life up to 300 min).
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: ~75% (as metabolites, <10% unchanged); Fecal: ~9%; Biliary: minor.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist